Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)

Tipranks - Tipranks - Sat Apr 4, 9:06PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT), Pharvaris (PHVS) and Amgen (AMGN) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Medtronic (MDT)

In a report issued on April 2, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Medtronic, with a price target of $118.00. The company’s shares closed last Thursday at $86.63.

According to TipRanks.com, Chadha is a 3-star analyst with an average return of 0.8% and a 45.8% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Edwards Lifesciences. ;'>

Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $109.80, implying a 27.9% upside from current levels. In a report issued on March 20, TipRanks – PerPlexity also upgraded the stock to Buy with a $102.00 price target.

See today’s best-performing stocks on TipRanks >>

Pharvaris (PHVS)

RBC Capital analyst Nevin Varghese maintained a Buy rating on Pharvaris on April 2 and set a price target of $51.00. The company’s shares closed last Thursday at $28.56.

Pharvaris has an analyst consensus of Strong Buy, with a price target consensus of $45.50.

Amgen (AMGN)

RBC Capital analyst Luca Issi maintained a Buy rating on Amgen on April 2 and set a price target of $360.00. The company’s shares closed last Thursday at $347.94.

According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -3.9% and a 36.8% success rate. Issi covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and Lexeo Therapeutics, Inc. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $367.45, representing a 4.2% upside. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $385.00 price target.

Read More on MDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).